title: Investigations into the prevention of neonatal Toxocara canis infections in puppies by application of doramectin to the bitch.
abstract: The aim of this investigation was to examine whether the treatment of bitches with doramectin is able to prevent pre-natal and galactogenic infections with Toxocara canis in their pups. Five experimentally infected beagle bitches were treated subcutaneously with 1 mg doramectin per kg body weight on each of days 40 and 55 of their pregnancy. Another infected bitch served as an untreated control. The efficacy of the medication was examined by counting the intestinal stages and somatic larvae in bitches and pups. The treatment did not completely prevent perinatal infections with T. canis. Intestinal stages and/or somatic larvae occurred in 16 of 20 pups. Seven pups developed patent infections. Compared to the control pups, the average worm burden (intestinal stages) of pups from treated bitches was less than 1%. No impairment of condition or physical development was noticed in the pups during the investigations. From the second week of life, the pups of the non-medicated bitch showed signs of a severe toxocarosis. No side effects were seen in the bitches after treatment with doramectin.
authors.affiliation: Institute of Parasitology, School of Veterinary Medicine, Hannover, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Schnieder
authors.forename: S
authors.initials: S
authors.lastname: Kordes
authors.forename: C
authors.initials: C
authors.lastname: Epe
authors.forename: S
authors.initials: S
authors.lastname: Kuschfeldt
authors.forename: M
authors.initials: M
authors.lastname: Stoye
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000469:parasitology*; D000871:Anthelmintics / Q000008:administration & dosage / Q000592:standards / Q000627:therapeutic use*; D001835:Body Weight / Q000502:physiology; D004283:Dog Diseases / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D004285:Dogs; D004804:Eosinophils / Q000166:cytology; D005260:Female; D007279:Injections, Subcutaneous; D007422:Intestines / Q000469:parasitology; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000592:standards / Q000627:therapeutic use; D007958:Leukocyte Count; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D017166:Toxocara canis / Q000302:isolation & purification*; D014120:Toxocariasis / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D000871:Anthelmintics; D007559:Ivermectin; C084101:doramectin